ErieViewer148 - Regarding your comment "Research reports are irrelevant"
In all of the SEC 10k and 10Q filings since they curtailed operations in February 2018:
We are dependent upon third parties to develop our product candidates, and such parties are, to some extent, outside of our control.
We depend upon independent contract research organizations, investigators and collaborators, such as universities and medical institutions, to conduct our pre-clinical and clinical studies.
Both Reverse splits were minimal. Most recent split was 1/25 compared to what they could have down 1/500.
A company sells shares to raise money.
Until they release updated Share information its hard to make any assumptions about who is getting paid. They only have 1 employee, Mr. Cain, who's employment will not receive any compensation at this time per SEC filings and no overhead costs.
Market Manipulators and day traders are the ones making quick minimal profits unfortunately.
They got rid of Chris Lowe and FLG who did nothing for the company but change its name, got mixed up with Milost Global scam and authorized 2 Reverse Splits. Mr. Lowe's first and only Investor presentation Oct. 2016 was a copy of Craig Dionne's presentation from Sept. 2015. Only significant change was the company name and logo from Genspera to Inspyr Therapeutics.
I do agree the amount you and I lost sucks.
I've learned some things from this stock play.
I hope you have also.
I believe in the independent research that I hope will one day transform this stock.
Until than Good Luck Investing.
